Early comfort care for multiple myeloma and aggressive lymphoma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study offers a palliative care team (doctors and nurses focused on comfort and quality of life) to people newly diagnosed with multiple myeloma or with an aggressive lymphoma that has come back. The goal is to help manage symptoms early, so you feel better and stay stronger during your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have either newly diagnosed multiple myeloma, or myeloma that needs a new treatment line, or aggressive lymphoma that has come back after one prior treatment
- You are able to walk and care for yourself (with help if needed) – a performance status of 0, 1, 2, or 3
- You are willing to fill out a short symptom questionnaire
- You have at least one symptom (like pain, tiredness, or nausea) that you rate as 3 or higher on a 0-10 scale
- You are not already receiving care from a palliative care team, and you can communicate well in English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
This trial studies whether adding palliative care (comfort-focused care to reduce stress and symptoms) helps people during adoptive cell therapy for blood cancers. It may help improve quality of life while you’re receiving the therapy.
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.